ITEOS THERAPEUTICS INC ITOS
COM · Common Stock · CUSIP 46565G104 · ISIN US46565G1040
* Summed across managers. Shares that two managers' reports both contain – a subsidiary's holdings that its parent's report includes too, or a sub-adviser's in its client's – are counted once. Holder counts are more reliable.
Trends to Q4 2025
Institutional holders
Managers reporting a position, each quarter
Numbers
| Quarter | Holders |
|---|---|
| Q3 2022 | 144 |
| Q4 2022 | 147 |
| Q1 2023 | 154 |
| Q2 2023 | 147 |
| Q3 2023 | 145 |
| Q4 2023 | 139 |
| Q1 2024 | 137 |
| Q2 2024 | 140 |
| Q3 2024 | 152 |
| Q4 2024 | 138 |
| Q1 2025 | 133 |
| Q2 2025 | 138 |
| Q3 2025 | 1 |
| Q4 2025 | 0 |
Buyers vs sellers
Managers adding to or starting a position, vs cutting or selling out
Numbers
| Quarter | Bought or added | Cut or sold out |
|---|---|---|
| Q1 2024 | 51 | 74 |
| Q2 2024 | 69 | 64 |
| Q3 2024 | 80 | 55 |
| Q4 2024 | 70 | 84 |
| Q1 2025 | 60 | 66 |
| Q2 2025 | 96 | 65 |
| Q3 2025 | 1 | 134 |
| Q4 2025 | 0 | 1 |
Calls vs puts
Options held, notional value, last 4 quarters. P/C = puts ÷ calls
Numbers
| Quarter | Calls | Puts | P/C |
|---|---|---|---|
| Q1 2025 | $1.0m | $4.7m | 4.55 |
| Q2 2025 | $8.5m | $8.7m | 1.03 |
| Q3 2025 | $0 | $0 | — |
| Q4 2025 | $0 | $0 | — |
Biggest buyers
| None |
Biggest sellers
| IFP Advisors, Inc | Sold out | -232 |
Major shareholders (over 5%)
Anyone who owns more than 5% of a class of the company's shares has to say so: on Schedule 13D if they may try to influence or control the company, on 13G if they're a passive investor, and update it as the stake changes. Each holder's latest filing, from 19 Dec 2024 on; percentages are of the share class, as the holder worked them out.
| Holder | Stake |
|---|---|
TANG CAPITAL MANAGEMENT LLC
13D · may seek influence
+90.0 pts · filed 2025-09-03
Stated purposeItem 4 of the Schedule 13D is amended by adding the following: Closing of the Merger: As previously disclosed, each of Concentra, the Issuer and Merger Sub entered into the Merger Agreement, which provides for an Offer by Merger Sub for all of the Issuer's Common Stock. The Offer commenced on August 1, 2025. On August 29, 2025, the Offer expired and Merger Sub accepted for purchase a total of 32,226,407 shares tendered and not withdrawn, representing approximately 72.17% of the total shares of the Issuer issued and outstanding. Following the expiration of the Offer, Merger Sub merged with and into the Issuer on August 29, 2025, pursuant to Section 251(h) of the Delaware General Corporation Law, and, among other things, each share of common stock of Merger Sub issued and outstanding immed… Full filing |
100.0% |
EcoR1 Capital, LLC
13D · may seek influence
+13.0 pts · filed 2025-05-16
Stated purposeAll of the Common Stock of the Issuer reported on this Schedule 13D was acquired in the ordinary course of business by the reporting persons for investment purposes. The reporting persons have no present plans or proposals that relate to or would result in any of the actions described in Item 4(a) through (j) of Schedule 13D. The reporting persons may evaluate on a continuing basis the investment in the Issuer and may, from time to time, acquire or dispose of Common Stock of the Issuer. Any such acquisitions or dispositions will depend upon (i) the price and availability of the Issuer's securities; (ii) subsequent developments concerning the Issuer's business and prospects and the industry in which the Issuer operates; (iii) investment policies of the reporting persons; (iv) other invest… Full filing |
27.9% |
| BlackRock Portfolio Management LLC 13G · institution new · filed 2025-04-15 | 6.1% |
| BlackRock, Inc. 13G · institution filed 2025-04-23 | 5.7% |
Fell to 5% or below in the last year: Ridgeback Capital Investments L.P. (0.0%, 2025-11-14)
Holders, Q4 2025
| Manager | Shares | Change |
|---|